Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Lenalidomide may reduce risk of progression from SMM to MMMay 16, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Quality of life decrement with salvage ASCT is short-livedApril 23, 2019Multiple MyelomaTransplantationLymphoma & Plasma Cell Disorders
ASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Real world responses mirror TOURMALINE-MM1 dataApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Combo could replace standard conditioning regimen for myelomaApril 2, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Oral triplet deemed effective in relapsed/refractory myelomaMarch 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma risk score has treatment-planning potentialMarch 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma therapies raise cardiovascular risksMarch 1, 2019Multiple MyelomaThrombosisLymphoma & Plasma Cell Disorders
MRD negativity linked to survival in MM after auto-HCTFebruary 24, 2019TransplantationMultiple MyelomaLymphoma & Plasma Cell Disorders
Similar results for once- or twice-weekly carfilzomib in MMFebruary 23, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
FDA approves daratumumab split-dosing regimen in MMFebruary 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Trial supports less aggressive myeloma treatmentFebruary 8, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Group proposes new grading systems for CRS, neurotoxicityJanuary 3, 2019Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaTransplantationALLNon-Hodgkin LymphomaAggressive Lymphomas
